GSK2606414

GSK2606414 has been studied in 3 papers since 2024: none in people yet, 2 in animals, 1 review; 2 in the past year. The research so far is in animals. The newest paper, Mar 28, 2026: “MFN2-PERK Axis Regulates ER Stress in Parotid Glands of Aged Mice via MAMs”.

Intervention

3 papers study it4 more mention it4 findingsUpdated

PubChemChEBI

See all 7 papers on GSK2606414

At a glance

The findings reach mice, none yet in people. 4 independent labs in 2 countries.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 4 independent labs in 2 countries
  • Funders: Guangdong Medical Research Foundation and 6 more
  • Animals2

What did studies of GSK2606414 find?

4

Studies of GSK2606414 measured 4 outcomes, among them ER unfolded protein response, bone microarchitecture deterioration and pancreatic toxicity.

ER unfolded protein response

downin mice1

1 study
  1. GSK2606414 inhibits ER unfolded protein response in mice.

    “Like 4-PBA, GSK2606414, a pharmacological antagonist of PERK, regulates ER stress and MAMs.”

    Animalsparotid gland

    MFN2-PERK Axis Regulates ER Stress in Parotid Glands of Aged Mice via MAMs

    Journal of dental research

More on ER unfolded protein response

Bone microarchitecture deterioration

upin mice1

1 study
  1. GSK2606414 increases bone microarchitecture deterioration in choline-supplemented ovariectomized mice.

    “Inhibition of PERK markedly worsened bone microarchitecture deterioration”

    Animalsin choline-supplemented ovariectomized micebonefemales

    Targeting gut-microbiota-dependent choline metabolite trimethylamine N-oxide ameliorates bone health in ovariectomized mice

    Life sciences

Pancreatic toxicity

upin mammalian1

1 study
  1. GSK2606414 induces pancreatic toxicity in mammalian.

    “systemic PERK inhibition produced pancreatic and other exocrine toxicities at higher exposures”

    Reviewhigher exposures

    Directional Modulation of the Integrated Stress Response in Neurodegeneration: A Systematic Review of eIF2B Activators, PERK-Pathway Agents, and ISR Prolongers

    Biomedicines

Exercise capacity

upin mice1

1 study
  1. GSK2606414 improves exercise capacity in mice with CPNE1 overexpression.

    “These effects were reversed by PERK inhibitor GSK2606414.”

    Animalsin mice with CPNE1 overexpression

    CPNE1 regulates myogenesis through the PERK-eIF2α pathway mediated by endoplasmic reticulum stress

    Cell and tissue research

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 2Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 04 papers in 12 months